Radiolabeled somatostatin analogs in prostate cancer

Mathew L. Thakur; H. Kolan; J. Li; R. Wiaderkiewicz; V. R. Pallela; R. Duggaraju; A. V. Schally

doi:10.1016/S0969-8051(96)00180-1

Radiolabeled somatostatin analogs in prostate cancer

Mathew L. Thakur, H. Kolan, J. Li, R. Wiaderkiewicz, V. R. Pallela, R. Duggaraju, A. V. Schally

Pathology

Research output: Contribution to journal › Article

50 Scopus citations

Abstract

Vapreotide (RC-160), a somatostatin analog, was labeled with ^99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, ¹¹¹InDTPA-D-Phe-Octreotide (¹¹¹In-DTPA-octreotide) served as a standard and ^99mTc-oxytocin as a receptor-non-specific control. ^99mTc-octreotide was also used. The 24 h tumor uptake of ^99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of ¹¹¹In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of ^99mTc-RC-160 was also higher than that of ¹¹¹In-DTPA-octreotide. The uptake of ^99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

Original language	English (US)
Pages (from-to)	105-113
Number of pages	9
Journal	Nuclear Medicine and Biology
Volume	24
Issue number	1
DOIs	https://doi.org/10.1016/S0969-8051(96)00180-1
State	Published - Jan 1 1997

Fingerprint

Keywords

Tc labeled octreotide
Tc labeled RC-160
imaging prostate cancer
radiolabeled somatostatin analogs
receptor specific peptides in prostate cancer

ASJC Scopus subject areas

Cancer Research
Molecular Medicine
Radiology Nuclear Medicine and imaging

Cite this

Thakur, M. L., Kolan, H., Li, J., Wiaderkiewicz, R., Pallela, V. R., Duggaraju, R., & Schally, A. V. (1997). Radiolabeled somatostatin analogs in prostate cancer. Nuclear Medicine and Biology, 24(1), 105-113. https://doi.org/10.1016/S0969-8051(96)00180-1

@article{a24d6aa7486449cd8c9328a1b86dd8bf,

title = "Radiolabeled somatostatin analogs in prostate cancer",

abstract = "Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.",

keywords = "Tc labeled octreotide, Tc labeled RC-160, imaging prostate cancer, radiolabeled somatostatin analogs, receptor specific peptides in prostate cancer",

author = "Thakur, {Mathew L.} and H. Kolan and J. Li and R. Wiaderkiewicz and Pallela, {V. R.} and R. Duggaraju and Schally, {A. V.}",

year = "1997",

month = jan

day = "1",

doi = "10.1016/S0969-8051(96)00180-1",

language = "English (US)",

volume = "24",

pages = "105--113",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Radiolabeled somatostatin analogs in prostate cancer

AU - Thakur, Mathew L.

AU - Kolan, H.

AU - Li, J.

AU - Wiaderkiewicz, R.

AU - Pallela, V. R.

AU - Duggaraju, R.

AU - Schally, A. V.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

AB - Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTc by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111InDTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 h tumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one μg of the peptide (200 Ci/mmol) was administered.

KW - Tc labeled octreotide

KW - Tc labeled RC-160

KW - imaging prostate cancer

KW - radiolabeled somatostatin analogs

KW - receptor specific peptides in prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0030975591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030975591&partnerID=8YFLogxK

U2 - 10.1016/S0969-8051(96)00180-1

DO - 10.1016/S0969-8051(96)00180-1

M3 - Article

C2 - 9080482

AN - SCOPUS:0030975591

VL - 24

SP - 105

EP - 113

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 1

ER -

Access to Document

10.1016/S0969-8051(96)00180-1